Search

Your search keyword '"Zhao,Jinge"' showing total 345 results
Start Over Author "Zhao,Jinge"
345 results on '"Zhao,Jinge"'

8. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma

Author

Liang, Jiayu, Sun, Guangxi, Pan, Xiuyi, Zhang, Mengni, Shen, Pengfei, Zhu, Sha, Zhao, Jinge, Zheng, Linmao, Zhao, Junjie, Chen, Yuntian, Yin, Xiaoxue, Chen, Junru, Hu, Xu, Zeng, Yuhao, Chen, Jianhui, Wang, Yongquan, Liu, Zhihong, Yao, Jin, Su, Minggang, Huang, Rui, Liao, Banghua, Wei, Qiang, Li, Xiang, Zhou, Qiao, Liu, Jiyan, Shen, Yali, Liu, Zhenhua, Chen, Ni, Zeng, Hao, and Zhang, Xingming

Published
2023
Full Text
View/download PDF

9. Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer

Author

Xu, Nanwei, Zhao, Jinge, Zhao, Fengnian, Liu, Haoyang, Yin, Wenlian, Zhu, Sha, Nie, Ling, Sun, Guangxi, Zheng, Linmao, Liu, Zhenhua, Cai, Diming, Chen, Junru, Dai, Jindong, Ni, Yuchao, Wang, Zhipeng, Zhang, Xingming, Liang, Jiayu, Chen, Yuntian, Hu, Xu, Pan, Xiuyi, Yin, Xiaoxue, Zhu, Xudong, Zhang, Yaowen, Wang, Zilin, Zeng, Yuhao, Wang, Minghao, Shen, Pengfei, Chen, Ni, and Zeng, Hao

Published
2023
Full Text
View/download PDF

11. Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes

Author

Ning, Shu, Zhao, Jinge, Lombard, Alan P, D’Abronzo, Leandro S, Leslie, Amy R, Sharifi, Masuda, Lou, Wei, Liu, Chengfei, Yang, Joy C, Evans, Christopher P, Corey, Eva, Chen, Hong-Wu, Yu, Aiming, Ghosh, Paramita M, and Gao, Allen C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Urologic Diseases, Stem Cell Research, Clinical Research, Stem Cell Research - Nonembryonic - Human, Cancer, Genetics, Detection, screening and diagnosis, Aetiology, 4.1 Discovery and preclinical testing of markers and technologies, 2.1 Biological and endogenous factors, Prostate, Prostate cancer
Abstract

BackgroundTreatment-emergent neuroendocrine prostate cancer (NEPC) after androgen receptor (AR) targeted therapies is an aggressive variant of prostate cancer with an unfavorable prognosis. The underlying mechanisms for early neuroendocrine differentiation are poorly defined and diagnostic and prognostic biomarkers are needed.MethodsWe performed transcriptomic analysis on the enzalutamide-resistant prostate cancer cell line C4-2B MDVR and NEPC patient databases to identify neural lineage signature (NLS) genes. Correlation of NLS genes with clinicopathologic features was determined. Cell viability was determined in C4-2B MDVR and H660 cells after knocking down ARHGEF2 using siRNA. Organoid viability of patient-derived xenografts was measured after knocking down ARHGEF2.ResultsWe identify a 95-gene NLS representing the molecular landscape of neural precursor cell proliferation, embryonic stem cell pluripotency, and neural stem cell differentiation, which may indicate an early or intermediate stage of neuroendocrine differentiation. These NLS genes positively correlate with conventional neuroendocrine markers such as chromogranin and synaptophysin, and negatively correlate with AR and AR target genes in advanced prostate cancer. Differentially expressed NLS genes stratify small-cell NEPC from prostate adenocarcinoma, which are closely associated with clinicopathologic features such as Gleason Score and metastasis status. Higher ARGHEF2, LHX2, and EPHB2 levels among the 95 NLS genes correlate with a shortened survival time in NEPC patients. Furthermore, downregulation of ARHGEF2 gene expression suppresses cell viability and markers of neuroendocrine differentiation in enzalutamide-resistant and neuroendocrine cells.ConclusionsThe 95 neural lineage gene signatures capture an early molecular shift toward neuroendocrine differentiation, which could stratify advanced prostate cancer patients to optimize clinical treatment and serve as a source of potential therapeutic targets in advanced prostate cancer.

Published
2022

12. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling

Author

Liu, Chengfei, Armstrong, Cameron M, Ning, Shu, Yang, Joy C, Lou, Wei, Lombard, Alan P, Zhao, Jinge, Wu, Chun-Yi, Yu, Aiming, Evans, Christopher P, Tepper, Clifford G, Li, Pui-kai, and Gao, Allen C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Urologic Diseases, Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Aetiology, 2.1 Biological and endogenous factors, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CRPC). While these treatments are effective initially, resistance occurs frequently. Continued expression of androgen receptor (AR) and its variants such as AR-V7 despite AR-targeted therapy contributes to treatment resistance and cancer progression in advanced CRPC patients. This highlights the need for new strategies blocking continued AR signaling. Here, we identify a novel AR/AR-V7 degrader (ARVib) and found that ARVib effectively degrades AR/AR-V7 protein and attenuates AR/AR-V7 downstream target gene expression in prostate cancer cells. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation. ARVib suppresses HSP70 expression and promotes STUB1 nuclear translocation, where STUB1 binds to AR/AR-V7 and promotes its ubiquitination and degradation. ARVib significantly inhibits resistant prostate tumor growth and improves enzalutamide treatment in vitro and in vivo. These data suggest that ARVib has potential for development as an AR/AR-V7 degrader to treat resistant CRPC.

Published
2021

14. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.

Author

Armstrong, Cameron M, Liu, Chengfei, Liu, Liangren, Yang, Joy C, Lou, Wei, Zhao, Ruining, Ning, Shu, Lombard, Alan P, Zhao, Jinge, D'Abronzo, Leandro S, Evans, Christopher P, Li, Pui-Kai, and Gao, Allen C

Subjects
Cell Line, Tumor, Humans, Prostatic Neoplasms, Benzamides, Nitriles, Phenylthiohydantoin, Androstenes, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, Androgen Antagonists, Steryl-Sulfatase, Androgens, Neoplasm Staging, Cell Proliferation, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Male, Prostatic Neoplasms, Castration-Resistant, Carcinogenesis, RNA-Seq, Aging, Genetics, Clinical Research, Urologic Diseases, Cancer, Prostate Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeMost patients with prostate cancer receiving enzalutamide or abiraterone develop resistance. Clinical evidence indicates that serum levels of dehydroepiandrosterone sulfate (DHEAS) and biologically active DHEA remain in the high range despite antiandrogen treatment. The conversion of DHEAS into DHEA by steroid sulfatase (STS) may contribute to sustained intracrine androgen synthesis. Here, we determine the contribution of STS to treatment resistance and explore the potential of targeting STS to overcome resistance in prostate cancer.Experimental designSTS expression was examined in patients and cell lines. In vitro, STS activity and expression were modulated using STS-specific siRNA or novel STS inhibitors (STSi). Cell growth, colony formation, androgen production, and gene expression were examined. RNA-sequencing analysis was conducted on VCaP cells treated with STSi. Mice were treated with STSis with or without enzalutamide to determine their effects in vivo.ResultsSTS is overexpressed in patients with castration-resistant prostate cancer (CRPC) and resistant cells. STS overexpression increases intracrine androgen synthesis, cell proliferation, and confers resistance to enzalutamide and abiraterone. Inhibition of STS using siRNA suppresses prostate cancer cell growth. Targeting STS activity using STSi inhibits STS activity, suppresses androgen receptor transcriptional activity, and reduces the growth of resistant C4-2B and VCaP prostate cancer cells. STSis significantly suppress resistant VCaP tumor growth, decrease serum PSA levels, and enhance enzalutamide treatment in vitro and in vivo.ConclusionsThese studies suggest that STS drives intracrine androgen synthesis and prostate cancer proliferation. Targeting STS represents a therapeutic strategy to treat CRPC and improve second-generation antiandrogen therapy.

Published
2020

15. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

Author

Zhao, Jinge, Ning, Shu, Lou, Wei, Yang, Joy C, Armstrong, Cameron M, Lombard, Alan P, D'Abronzo, Leandro S, Evans, Christopher P, Gao, Allen C, and Liu, Chengfei

Subjects
Cancer, Clinical Research, Urologic Diseases, Prostate Cancer, Aging, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Aldo-Keto Reductase Family 1 Member C3, Alternative Splicing, Androgen Receptor Antagonists, Apoptosis, Biomarkers, Tumor, Cell Proliferation, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Male, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Tumor Cells, Cultured, Oncology and Carcinogenesis, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis
Abstract

The next-generation antiandrogen drugs, XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide) and NUBEQA (darolutamide) extend survival times and improve quality of life in patients with advanced prostate cancer. Despite these advances, resistance occurs frequently and there is currently no definitive cure for castration-resistant prostate cancer. Our previous studies identified that similar mechanisms of resistance to enzalutamide or abiraterone occur following treatment and cross-resistance exists between these therapies in advanced prostate cancer. Here, we show that enzalutamide- and abiraterone-resistant prostate cancer cells are further cross-resistant to apalutamide and darolutamide. Mechanistically, we have determined that the AKR1C3/AR-V7 axis confers this cross-resistance. Knockdown of AR-V7 in enzalutamide-resistant cells resensitize cells to apalutamide and darolutamide treatment. Furthermore, targeting AKR1C3 resensitizes resistant cells to apalutamide and darolutamide treatment through AR-V7 inhibition. Chronic apalutamide treatment in C4-2B cells activates the steroid hormone biosynthesis pathway and increases AKR1C3 expression, which confers resistance to enzalutamide, abiraterone, and darolutamide. In conclusion, our results suggest that apalutamide and darolutamide share similar resistant mechanisms with enzalutamide and abiraterone. The AKR1C3/AR-V7 complex confers cross-resistance to second-generation androgen receptor-targeted therapies in advanced prostate cancer.

Published
2020

18. Avoiding unnecessary biopsy: Development of a predictive calculator to identify non-prostate cancer in patients with Prostate Imaging Reporting and Data System category ≥ 4 lesions.

Author

Zeng, Hong, primary, Chen, Yuntian, additional, Xie, Yandong, additional, Dai, Jindong, additional, Wang, Minghao, additional, Wang, Qian, additional, Xu, Nanwei, additional, Chen, Junru, additional, Sun, Guangxi, additional, Zhao, Jinge, additional, Zeng, Hao, additional, and Shen, Pengfei, additional

Published
2024
Full Text
View/download PDF

20. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)

Author

Zhu, Sha, Zhao, Jinge, Nie, Ling, Yin, Wenlian, Zhang, Yaowen, Zhao, Fengnian, Ni, Yuchao, Zhang, Xingming, Wang, Zhipeng, Dai, Jindong, Liu, Zhenhua, Chen, Junru, Zeng, Yuhao, Wang, Zilin, Sun, Guangxi, Liang, Jiayu, Zhao, Xiaochen, Zhu, Xudong, Tao, Ronggui, Yang, Jiyu, He, Ben, Chen, Ni, Shen, Pengfei, and Zeng, Hao

Published
2022
Full Text
View/download PDF

23. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67

Author

Zhao, Fengnian, primary, Zhao, Jinge, additional, Wei, Xinyuan, additional, Shi, Yifu, additional, Xu, Nanwei, additional, Zhu, Sha, additional, Chen, Junru, additional, Sun, Guangxi, additional, Dai, Jindong, additional, Wang, Zhipeng, additional, Zhang, Xingming, additional, Liang, Jiayu, additional, Hu, Xu, additional, Liu, Haoyang, additional, Zhao, Junjie, additional, Liu, Zhenhua, additional, Nie, Ling, additional, Shen, Pengfei, additional, Chen, Ni, additional, and Zeng, Hao, additional

Published
2024
Full Text
View/download PDF

26. Data from Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate

Author

Zhao, Jinge, primary, Xu, Nanwei, primary, Zhu, Sha, primary, Nie, Ling, primary, Zhang, Mengni, primary, Zheng, Linmao, primary, Cai, Diming, primary, Sun, Xiaomeng, primary, Chen, Junru, primary, Dai, Jindong, primary, Ni, Yuchao, primary, Wang, Zhipeng, primary, Zhang, Xingming, primary, Liang, Jiayu, primary, Chen, Yuntian, primary, Hu, Xu, primary, Pan, Xiuyi, primary, Yin, Xiaoxue, primary, Liu, Haoyang, primary, Zhao, Fengnian, primary, Zhang, Bei, primary, Chen, Hao, primary, Miao, Jiashun, primary, Qin, Cong, primary, Zhao, Xiaochen, primary, Yao, Jin, primary, Liu, Zhenhua, primary, Liao, Banghua, primary, Wei, Qiang, primary, Li, Xiang, primary, Liu, Jiyan, primary, Gao, Allen C., primary, Huang, Haojie, primary, Shen, Pengfei, primary, Chen, Ni, primary, Zeng, Hao, primary, and Sun, Guangxi, primary

Published
2024
Full Text
View/download PDF

27. Table S7 from Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate

Author

Zhao, Jinge, primary, Xu, Nanwei, primary, Zhu, Sha, primary, Nie, Ling, primary, Zhang, Mengni, primary, Zheng, Linmao, primary, Cai, Diming, primary, Sun, Xiaomeng, primary, Chen, Junru, primary, Dai, Jindong, primary, Ni, Yuchao, primary, Wang, Zhipeng, primary, Zhang, Xingming, primary, Liang, Jiayu, primary, Chen, Yuntian, primary, Hu, Xu, primary, Pan, Xiuyi, primary, Yin, Xiaoxue, primary, Liu, Haoyang, primary, Zhao, Fengnian, primary, Zhang, Bei, primary, Chen, Hao, primary, Miao, Jiashun, primary, Qin, Cong, primary, Zhao, Xiaochen, primary, Yao, Jin, primary, Liu, Zhenhua, primary, Liao, Banghua, primary, Wei, Qiang, primary, Li, Xiang, primary, Liu, Jiyan, primary, Gao, Allen C., primary, Huang, Haojie, primary, Shen, Pengfei, primary, Chen, Ni, primary, Zeng, Hao, primary, and Sun, Guangxi, primary

Published
2024
Full Text
View/download PDF

28. Table S1-revised from Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate

Author

Zhao, Jinge, primary, Xu, Nanwei, primary, Zhu, Sha, primary, Nie, Ling, primary, Zhang, Mengni, primary, Zheng, Linmao, primary, Cai, Diming, primary, Sun, Xiaomeng, primary, Chen, Junru, primary, Dai, Jindong, primary, Ni, Yuchao, primary, Wang, Zhipeng, primary, Zhang, Xingming, primary, Liang, Jiayu, primary, Chen, Yuntian, primary, Hu, Xu, primary, Pan, Xiuyi, primary, Yin, Xiaoxue, primary, Liu, Haoyang, primary, Zhao, Fengnian, primary, Zhang, Bei, primary, Chen, Hao, primary, Miao, Jiashun, primary, Qin, Cong, primary, Zhao, Xiaochen, primary, Yao, Jin, primary, Liu, Zhenhua, primary, Liao, Banghua, primary, Wei, Qiang, primary, Li, Xiang, primary, Liu, Jiyan, primary, Gao, Allen C., primary, Huang, Haojie, primary, Shen, Pengfei, primary, Chen, Ni, primary, Zeng, Hao, primary, and Sun, Guangxi, primary

Published
2024
Full Text
View/download PDF

29. Supplementary Data from Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate

Author

Zhao, Jinge, primary, Xu, Nanwei, primary, Zhu, Sha, primary, Nie, Ling, primary, Zhang, Mengni, primary, Zheng, Linmao, primary, Cai, Diming, primary, Sun, Xiaomeng, primary, Chen, Junru, primary, Dai, Jindong, primary, Ni, Yuchao, primary, Wang, Zhipeng, primary, Zhang, Xingming, primary, Liang, Jiayu, primary, Chen, Yuntian, primary, Hu, Xu, primary, Pan, Xiuyi, primary, Yin, Xiaoxue, primary, Liu, Haoyang, primary, Zhao, Fengnian, primary, Zhang, Bei, primary, Chen, Hao, primary, Miao, Jiashun, primary, Qin, Cong, primary, Zhao, Xiaochen, primary, Yao, Jin, primary, Liu, Zhenhua, primary, Liao, Banghua, primary, Wei, Qiang, primary, Li, Xiang, primary, Liu, Jiyan, primary, Gao, Allen C., primary, Huang, Haojie, primary, Shen, Pengfei, primary, Chen, Ni, primary, Zeng, Hao, primary, and Sun, Guangxi, primary

Published
2024
Full Text
View/download PDF

30. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma

Author

Sun, Guangxi, Chen, Junru, Liang, Jiayu, Yin, Xiaoxue, Zhang, Mengni, Yao, Jin, He, Ning, Armstrong, Cameron M., Zheng, Linmao, Zhang, Xingming, Zhu, Sha, Sun, Xiaomeng, Yang, Xiaoxia, Zhao, Wanbin, Liao, Banghua, Pan, Xiuyi, Nie, Ling, Yang, Ling, Chen, Yuntian, Zhao, Jinge, Zhang, Haoran, Dai, Jindong, Shen, Yali, Liu, Jiyan, Huang, Rui, Liu, Jiandong, Wang, Zhipeng, Ni, Yuchao, Wei, Qiang, Li, Xiang, Zhou, Qiao, Huang, Haojie, Liu, Zhenhua, Shen, Pengfei, Chen, Ni, and Zeng, Hao

Published
2021
Full Text
View/download PDF

32. Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate

Author

Zhao, Jinge, primary, Zhu, Sha, additional, Nie, Ling, additional, Zhang, Mengni, additional, Zheng, Linmao, additional, Xu, Nanwei, additional, Cai, Diming, additional, Sun, Xiaomeng, additional, Chen, Junru, additional, Dai, Jindong, additional, Ni, Yuchao, additional, Wang, Zhipeng, additional, Zhang, Xingming, additional, liang, jiayu, additional, Chen, Yuntian, additional, Hu, Xu, additional, Pan, Xiuyi, additional, Yin, Xiaoxue, additional, Liu, Haoyang, additional, Zhao, Fengnian, additional, Zhang, Bei, additional, Chen, Hao, additional, Miao, Jiashun, additional, Qin, Cong, additional, Zhao, Xiaochen, additional, Yao, Jin, additional, Liu, Zhenhua, additional, Liao, Banghua, additional, Wei, Qiang, additional, Li, Xiang, additional, Liu, Jiyan, additional, Gao, Allen C., additional, Huang, Haojie, additional, Shen, Peng-fei, additional, Chen, Ni, additional, Zeng, Hao, additional, and Sun, Guangxi, additional

Published
2023
Full Text
View/download PDF

36. Synergistic Passivation via Lewis Coordination and Electrostatic Interaction for Efficient Perovskite Solar Cells

Author

Yan, Guangyuan, primary, Ma, Zhu, additional, Liu, Qianyu, additional, Hou, Shanyue, additional, Li, Yanlin, additional, Liu, Run, additional, Huang, Dejun, additional, Hou, Tian, additional, Qiu, Qingqing, additional, Du, Zhuowei, additional, Yang, Junbo, additional, Chen, Yi, additional, You, Wei, additional, Luo, Hong, additional, Zhao, Jinge, additional, Xiang, Yan, additional, Zhang, Wenfeng, additional, Yu, Jian, additional, Huang, Yuelong, additional, and Mai, Yaohua, additional

Published
2023
Full Text
View/download PDF

46. PD24-09 PHASE II, MULTI-CENTER STUDY OF SINTILIMAB IN COMBINATION WITH AXITINIB IN PATIENTS WITH ADVANCED FUMARATE HYDRATASE-DEFICIENT RENAL CELL CARCINOMA

Author

Zhang, Xingming, primary, Liu, Haoyang, additional, Zhang, Yaowen, additional, Zhao, Junjie, additional, Chen, Yuntian, additional, Zeng, Yuhao, additional, Wang, Zilin, additional, Sun, Guangxi, additional, Liang, Jiayu, additional, Zhu, Sha, additional, Zhao, Jinge, additional, Zheng, Linmao, additional, Yin, Xiaoxue, additional, Chen, Junru, additional, Hu, Xu, additional, Sheng, Xinan, additional, Wang, Yongquan, additional, Gong, Kan, additional, Liu, Xiaodong, additional, Huang, Rui, additional, Wei, Qiang, additional, Li, Xiang, additional, Liu, Jiyan, additional, Shen, Pengfei, additional, Chen, Ni, additional, Yao, Jin, additional, Liu, Zhenhua, additional, and Zeng, Hao, additional

Published
2023
Full Text
View/download PDF

47. Supplementary Figure S1 from Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer

Author

Armstrong, Cameron M., primary, Liu, Chengfei, primary, Liu, Liangren, primary, Yang, Joy C., primary, Lou, Wei, primary, Zhao, Ruining, primary, Ning, Shu, primary, Lombard, Alan P., primary, Zhao, Jinge, primary, D'Abronzo, Leandro S., primary, Evans, Christopher P., primary, Li, Pui-Kai, primary, and Gao, Allen C., primary

Published
2023
Full Text
View/download PDF

48. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer

Author

Wang, Zhipeng, primary, Liu, Haoyang, additional, Zhao, Jinge, additional, Chen, Junru, additional, Zhu, Sha, additional, Dai, Jindong, additional, Ni, Yuchao, additional, Xu, Nanwei, additional, Zhao, Fengnian, additional, He, Ben, additional, Zhang, Xingming, additional, Liang, Jiayu, additional, Sun, Guangxi, additional, Liu, Zhenhua, additional, Shen, Pengfei, additional, and Zeng, Hao, additional

Published
2023
Full Text
View/download PDF

49. Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients

Author

Zeng,Yuhao, Zhu,Sha, Wang,Zilin, Chen,Junru, Dai,Jindong, Liu,Zhenhua, Sun,Guangxi, Liang,Jiayu, Zhang,Xingming, Wang,Zhipeng, Zhao,Jinge, Ni,Yuchao, Yang,Jiyu, Wang,Minghao, Wei,Qiang, Li,Xiang, Chen,Ni, Li,Zhiping, Wang,Xin, Shen,Yali, Yao,Jin, Huang,Rui, Liu,Jiyan, Cai,Diming, Zeng,Hao, Shen,Pengfei, Zeng,Yuhao, Zhu,Sha, Wang,Zilin, Chen,Junru, Dai,Jindong, Liu,Zhenhua, Sun,Guangxi, Liang,Jiayu, Zhang,Xingming, Wang,Zhipeng, Zhao,Jinge, Ni,Yuchao, Yang,Jiyu, Wang,Minghao, Wei,Qiang, Li,Xiang, Chen,Ni, Li,Zhiping, Wang,Xin, Shen,Yali, Yao,Jin, Huang,Rui, Liu,Jiyan, Cai,Diming, Zeng,Hao, and Shen,Pengfei

Abstract

Yuhao Zeng,1,* Sha Zhu,1,* Zilin Wang,1 Junru Chen,1 Jindong Dai,1 Zhenhua Liu,1 Guangxi Sun,1 Jiayu Liang,1 Xingming Zhang,1 Zhipeng Wang,1 Jinge Zhao,1 Yuchao Ni,1 Jiyu Yang,1 Minghao Wang,1 Qiang Wei,1 Xiang Li,1 Ni Chen,2 Zhiping Li,3 Xin Wang,3 Yali Shen,3 Jin Yao,4 Rui Huang,5 Jiyan Liu,6 Diming Cai,7 Hao Zeng,1 Pengfei Shen1 1Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 3Department of Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 4Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 5Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 6Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 7Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Pengfei Shen; Hao Zeng, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People’s Republic of China, Email cdhx510@163.com; kucaizeng@163.comPurpose: Multidisciplinary team (MDT) discussion is a widely used model to manage patients diagnosed with cancer. However, there has been no direct evidence to prove its effect on the prognosis of metastatic renal cell carcinoma (mRCC) patients, so this study explored the impact of MDT discussion on mRCC patient survival.Methods: The clinical data of 269 mRCC patients were retrospectively collected from 2012 to 2021. The cases were grouped into the MDT and non-MDT groups, then subgroup analysis was performed according to different histology types, as well as exploring the

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results